Natural history and impact of treatment with tafamidis on major cardiovascular outcome-free survival time in a cohort of patients with transthyretin amyloidosis.
Bézard M, Kharoubi M, Galat A, Poullot E, Guendouz S, Fanen P, Funalot B, Moktefi A, Lefaucheur JP, Abulizi M, Deux JF, Gendre T, Audard V, El Karoui K, Canoui-Poitrine F, Zaroui A, Itti E, Teiger E, Planté-Bordeneuve V, Oghina S, Damy T.
Bézard M, et al. Among authors: teiger e.
Eur J Heart Fail. 2021 Feb;23(2):264-274. doi: 10.1002/ejhf.2028. Epub 2020 Nov 9.
Eur J Heart Fail. 2021.
PMID: 33094885
Free article.